Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Liabilities and Shareholders Equity (2023 - 2025)

Historic Liabilities and Shareholders Equity for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $322.0 million.

  • Zenas BioPharma's Liabilities and Shareholders Equity fell 2018.04% to $322.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 17964.45%. This contributed to the annual value of $370.0 million for FY2024, which is 44263.42% up from last year.
  • Zenas BioPharma's Liabilities and Shareholders Equity amounted to $322.0 million in Q3 2025, which was down 2018.04% from $293.1 million recorded in Q2 2025.
  • Zenas BioPharma's 5-year Liabilities and Shareholders Equity high stood at $403.4 million for Q3 2024, and its period low was $68.2 million during Q4 2023.
  • Its 3-year average for Liabilities and Shareholders Equity is $298.4 million, with a median of $327.9 million in 2025.
  • In the last 5 years, Zenas BioPharma's Liabilities and Shareholders Equity skyrocketed by 44263.42% in 2024 and then plummeted by 2018.04% in 2025.
  • Quarter analysis of 3 years shows Zenas BioPharma's Liabilities and Shareholders Equity stood at $68.2 million in 2023, then soared by 442.63% to $370.0 million in 2024, then fell by 12.96% to $322.0 million in 2025.
  • Its last three reported values are $322.0 million in Q3 2025, $293.1 million for Q2 2025, and $333.8 million during Q1 2025.